Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The European market for aortic repair devices will expand at a modest rate, driven primarily by endovascular procedure volume growth and continued development and adoption of aortic stent grafts. However, adoption of endovascular procedures will be hindered to some extent by doubts regarding the cost-effectiveness and long-term outcomes of these procedures.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for aortic repair devices in Europe across a 10-year period.
Treatment of aortic aneurysms is rising in Europe due to improved diagnosis and patient awareness, contributing to procedure volumes.
Which segment of the aortic repair device market will see the greatest increase in procedure volumes through 2027?
For which indications will procedure volume growth be limited and which factors limit growth?
Which country will see the fastest procedure volume growth and which will see slowest growth?
What effect will NICE's newly drafted guidelines regarding AAA repair have on treatment decisions in the UK and the rest of Europe?
Aortic repair can be performed using endovascular, surgical, or hybrid procedures.
Which methods are preferred for which indications? How does this compare across the countries in Europe?
What are the main drivers and limiters of growth in the endovascular device market?
For which indication will the growth of endovascular procedures be limited and why?
Which country has the highest penetration of endovascular procedures?
The aortic stent graft market is characterized by innovation, with companies launching products designed to address unmet needs.
What new products are entering the European market?
How will these launches affect the competitive landscape?
What impact will this have on the market for surgical grafts?
Already a Client? Log in to access this report.
Yang Yun Li is an analyst within the Cardiovascular Medtech Insights team at Decision Resources Group, specializing in clot management device markets. Yang holds a in Pharmaceutical Sciences from the University of Toronto.